US Patent 11629189 Bispecific antibody for ICOS and PD-L1

Patent 11629189 was granted and assigned to Kymab on April, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 4 Jan, 2024

"update inverses"

Golden AI

edited on 4 Jan, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11858996 Anti-ICOS antibodies

Edits on 14 Aug, 2023

"Add patent inventor"

Golden AI

edited on 14 Aug, 2023

Edits made to:

Infobox (+10 properties)

Infobox

Patent Inventor Names

Fadi Badr0

Francisca Wollerton Van Horck0

Frederick Akele0

Jamie Iain Campbell0

Matthew John McCourt0

Mihriban Tuna0

Mustapha Faroudi0

Richard Charles Alfred Sainson0

Ryan Fiehler0

Stephen John Arkinstall0

Edits on 30 Apr, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 30 Apr, 2023

Infobox

Patent Citations

‌

US Patent 10517949 Anti-PD-L1 antibodies

Edits on 19 Apr, 2023

"Created via: Entity Importer"

Golden AI

created this topic on 19 Apr, 2023

Edits made to:

Infobox (+11 properties)

Article (+348 characters)

‌

US Patent 11629189 Bispecific antibody for ICOS and PD-L1

Article

Multispecific antibody in mAb2 format, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. Use of the multispecific antibody in immuno-oncology, including for treatment of solid tumours. Combination therapy including antibody to another immune checkpoint molecule such as PD-1 and CTLA-4, in addition to anti-ICOS and anti-PD-L1.

Infobox

Is a